Reuters logo
BRIEF-FDA grants Orphan Drug Designation for Ganaxolone in CDKL5 disorder
June 29, 2017 / 6:32 PM / 5 months ago

BRIEF-FDA grants Orphan Drug Designation for Ganaxolone in CDKL5 disorder

June 29 (Reuters) - Marinus Pharmaceuticals Inc:

* Marinus Pharmaceuticals says FDA grants orphan drug designation for ganaxolone in cdkl5 disorder

* Marinus Pharmaceuticals says FDA has granted Orphan Drug Designation to Ganaxolone for treatment of CDKL5 disorder

* Marinus Pharmaceuticals says Ganaxolone is currently being evaluated in children with CDKL5 disorder in a phase 2 clinical trial Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below